Advances of macrocyclic compounds in pharmaceutical sciences

Chinese Pharmaceutical Journal

Volumn 43, Issue 7, 2008, Pages

  Yu, Ke Gui ^a   Zhou, Cheng He ^a   Li, Dong Hong ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CRYPTOPHYIN DERIVATIVE; ELEUTHEROBIN; GALBONOLIDE A; HEAT SHOCK PROTEIN 90; MACROCYCLIC COMPOUND; RADANAMYCIN; SARCODICTYIN A; SARCODICTYIN B; TELOMESTATIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CARDIOVASCULAR SYSTEM; CHEMICAL STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS; NERVOUS SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW;

EID: 52749083185     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. LAMARRE D, ANDERSON P C, BAILEY M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with-hepatitis C virus [J]. Nature, 2003,426(6963):186-189.
2. BOTTRILL M, NICHOLAS L K, LONG N J. Lanthanides in magnetic resonance imaging [J]. Chem Soc Rev, 2006,35(6):557-571.
3. NOMURA T, IWAKI T, YASUKATA T, et al. A new type of ketolides bearing an N-ary L-alkyl acetamide moiety at the C-9 iminoether synthesis and structure-activity relationships [J]. Bioorg Med Chem, 2005,13(24):6615-6628.
4. NAM G, KANG T W, SHIN J H, et al. Design, synthesis, and anti-Helicobacter pylori activity of erythromycin A (E)-9-oxime ether derivatives [J]. Bioorg Med Chem Lett, 2006,16(3):569-572.
5. MARIANI R, GRANATA G, MAFFIOLI S I, et al. Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. Part 3: Chemical derivatization [J]. Bioorg Med Chem Lett, 2005,15(16):3748-3752.
6. LI Q L, HUANG J, WANG Q, et al. Monometallic complexes of 1, 4, 7, 10-tetraazacyclododecane containing animidazolium side; Synthesis, characterization, and their interaction with plasmid DNA [J]. Bioorg Med Chem, 2006,14(12):4151-4157.
7. WANG J W, SONG HB, LI Q S, et al. Macrocyclic dinuclear gold (I) and silver(I) NHCs complexes [J]. Inorg Chim Acta, 2005,358(13):3653- 3658.
8. SAKOH H, SUGIMOTO Y, IMAMURA H, et al. Novel galbonolide derivatives as IPC synthase inhibitors: design, synthesisand in vitro antifungal activities [J]. Bioorg Med Chem Lett, 2004,14(1):143-145.
9. ZHOU C H, BAI X, LI T Q, et al. Synthesis and antifungal activity of novel soluble gluco-fluconazole triazolium [J]. Chin J Org Chem, 2005,25(suppl):574-575.
10. LEE T Y, LE V D, LIM D Y, et al. Development of a new type of protease inhibitors, efficacious against FIV and HIV variants[J]. J Am Chem Soc, 1999,121(6):1145-1155.
11. MAK C C, BRIK A, LERNER D L, et al. Design and synthesis of broad-based mono- and bi- cyclic inhibitors of FIV and HIV proteases [J]. Bioorg Med Chem, 2003,11(9):2025-2040.
12. LIANG X Y, SADLER P J. Cyclam complexes and their applications in medicine [J]. Chem Soc Rev, 2004,33(4):246-266.
13. VLIEGHE P, CLERCl T, PANNECOUQUE C, et al. Synthesis of new covalently bound kappa-carrageenan-AZT conjugates with-improved anti-HIV activities [J]. J Med Chem, 2002,45(6):1275-1283.
14. FALARDEAU G, LACHANCE H, ST-PIERRE A, et al. Design and synthesis of a potent macrocyclic 1,6-naphthyridine anti-humancytomegalovirus (HCMV) inhibitors [J]. Bioorg Med Chem Lett, 2005,15(9):1693-1695.
15. TSANTRIZOS Y S, BOLGER G, BONNEAU P, et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection [J]. Angew Chem, 2003,42(12):1356-1360.
16. LLINAS-BRUNET M, BAILEY M D, BOLGER G, et al. Structure-activity study on a novel series of macrocyclic inhibitors of the Hepatitis C virus NS3 protease leading to the discovery of BILN 2061 [J]. J Med Chem, 2004,47(7):1605-1608.
17. WANG J X, GU Q L, YOU Q D, et al. Epothilones: A new class of antitumour agent [J]. Prog Pharm Sci, 2004,28(8):354-361.
18. CHANDRASEKHAR S, JAGADESHWAR V, NARSIHMULU C, et al. Design, synthesis and cytotoxic studies on the simplified oxy analog of eleutherobin [J]. Bioorg Med Chem Lett, 2004,14(14):3687-3689.
19. MINHAS G S, PILCH D S, KERRIGAN J E, et al. Synthesis and G-quadruplex stabilizing properties of a series ofoxazole-containing macrocycles [J]. Bioorg Med Chem Lett, 2006,16(15):3891-3895.
20. HITOTSUYANAGI Y, HASUDA T, AIHARA T, et al. Synthesis of [Gly-1] RA-VII, [Gly-2] RA-VII, and [Gly-4] RA-VII. Glycine-containing analogues of RA-VII, an antitumor bicyclic hexapeptide from rubia plants [J]. J Org Chem, 2004,69(5):1481-1486.
21. CHEUNG K M J, MATTHEWS T P, JAMES K, et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors [J]. Bioorg Med Chem Lett, 2005,15(14):3338-3343.
22. WANG M W, SHEN G, BLAGG B S J. Radanamycin, a macrocyclic chimera of radicicol and geldanamycin [J]. Bioorg Med Chem Lett, 2006,16(9):2459-2462.
23. CAMPHAUSEN K, SPROULL M, TANTAMA S, et al. Evaluation of chelating agents as anti-angiogenic therapy through copper chelation [J]. Bioorg Med Chem, 2004,12(19):5133-5140.
24. BELVISI L, BERNARDI A, COLOMBO M, et al. Targeting integrins; insights into structure and activity of cyclic RGDpentapeptide mimics containing azahicycloalkane amino acids [J]. Bioorg Med Chem, 2006,14(1):169-180.
25. MIRANDA C, ESCARTI F, LAMARQUE L, et al. New 1H-pyrazole- containing polyamine receptors able to complex L-glutamate in water at physiological pH values [J]. J Am Chem Soc, 2004,126(3):823-833.
26. MASUKO T, METORI K, KIZAWA Y, et al. Design and synthesis of a novel water-soluble NMDA receptor antagonist with a 1, 4, 7, 10-tetraazacyclododecane group [J]. Chem Pharm Bull, 2005,53(4):444-447.
27. PEPYS M B, HERBERT J, HUTCHINSON W L, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis [J]. Nature, 2002,417(6886):254-259.
28. ROJO I, MARTIN J A, BROUGHTON H, et al. Macrocyclic peptidomimetic inhibitors of β-secretase (BACE): First X-ray structure of a macrocyclic peptidomimetic-BACE complex [J]. Bioorg Med Chem Lett, 2006,16(1):191-195.
29. NANTERMET P G, BARROW J C, NEWTON C L, et al. Design and synthesis of potent and selective macrocyclic thrombin inhibitors [J]. Bioorg Med Chem Lett, 2003,13(16):2781-2784.
30. GOLDRING W P D, ALEXANDER S P H, KENDALL D A, et al. Novel phomactin analogues as PAF receptor ligands [J]. Bioorg Med Chem Lett, 2005,15(13):3263-3266.
31. KOESTER L S, BERTUOL J B, GROCK K R. Bioavailability of carbamazepine; beta-cyclodextrin complex in beagle dogsfrom hydroxypropylmethylcellulose matrix tablets [J]. Eur J Pharm Sci, 2004,22(2,3):201-207.
32. CASTRO HERMIDA J A, GOMEZ COUSO H, ARES MAZAS M E, et al. Anticryptosporidial activity of furan derivative G1 and its inclusion complexwith beta-cyclodextrin [J]. J Pharm Sci, 2004,93(1):197-206.
33. DAVIS M E, BREWSTER M E. Cyclodextrin-based pharmaceutics: past, present and future [J]. Nat Rev Drug Discov, 2004,3(12):1023-1035.
34. LIU Y, CHEN G S, CHEN Y, et al. Inclusion complexes of paclitaxel and oligo(ethylenediamino) bridged bis(β-cyclodextrin) s: solubilization and antitumor activity [J]. Bioorg Med Chem, 2004,12(22):5767-5775.
35. ZHANG M Q. Drug-specific cyclodextrins: the future of rapid neuromuscular blockreversal [J]. Drugs Fut, 2003,28(4):347-354.
36. FUJIMOTO K, MIYATA T, AOYAMA Y, et al. Saccharide-directed cell recognition and molecular delivery using macrocyclic saccharide clusters: Masking of hydrophobicity to enhanced the saccharide specificity [J]. J Am Chem Soc, 2000,122:3558-3559.
37. VELÁZQUEZ E, VIRUES C, INOUE M B, et al. NMR Studies of host guest complexes of anionic cyclophanes with dopamine and its analogues in aqueous media [J]. J Inclusion Phenom Macrocyclic Chem, 2004,48(3-4):141-146.
38. ZHOU C H, GU X R, XIE R G, et al. Convenient and efficient synthesis for a series of ether bis-imidazoles and their derivatives [J]. Synth Commun, 1999,29(7):1217-1222.
39. PARKER L L, LACY S M, FARRUGIA L J, et al. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs [J]. J Med Chem, 2004,47(23):5683-5689.
40. 3+ complexes of triaza macrocyclic ligands: biodistribution and clearance studies [J]. Nucl Med Biol, 1999,26(6):707-710.
41. CHONG H S, GARMESTAM K, JR L H B, et al. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging [J]. J Med Chem, 2006,49(6):2055-2062.
42. KUBICEK V, RUDOVSKY J, KOTEK J, et al. A bisphosphonate monoamide analogue of DOTA; a potential agent for bone targeting [J]. J Am Chem Soc, 2005,127(47):16477-16485.
43. ZHANG X L, WANG Y X, LI J Z, et al. Recent progress in application of polyazamacrocyclic compounds in radio-metals labeling [J]. Nucl Tech, 2004,27(5):391-395.
44. BOSWELL C A, SUN X K, NIU W J, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes[J]. J Med Chem, 2004,47(6):1465-1474.
45. FREIRIA A, BASTIDA R, VALENCIA L, et al. Metal complexes with two tri-aza, tri-oxa pendant-armed macrocyclic ligands: Synthesis, characterization, crystal structures and fluorescence studies [J]. Inorg Chim Acta, 2006,359(8):2383-2394.